{"id":"dexfosfoserine","rwe":[],"tags":[{"label":"dexfosfoserine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Metabotropic glutamate receptor 8","category":"target"},{"label":"GRM8","category":"gene"},{"label":"GRM6","category":"gene"},{"label":"GRM4","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"seriphos","offLabel":[],"synonyms":["phosphoserine","dexfosfoserine","fosforina","3-O-Phosphoserine","L-Phosphoserine","seriphos","L-serine-O-phosphate","L-SOP"],"timeline":[],"approvals":[],"brandName":"Seriphos","ecosystem":[],"mechanism":{"target":"Metabotropic glutamate receptor 6, Metabotropic glutamate receptor 7, Metabotropic glutamate receptor 4","targets":[{"gene":"GRM8","source":"DrugCentral","target":"Metabotropic glutamate receptor 8","protein":"Metabotropic glutamate receptor 8"},{"gene":"GRM6","source":"DrugCentral","target":"Metabotropic glutamate receptor 6","protein":"Metabotropic glutamate receptor 6"},{"gene":"GRM4","source":"DrugCentral","target":"Metabotropic glutamate receptor 4","protein":"Metabotropic glutamate receptor 4"},{"gene":"GRM7","source":"DrugCentral","target":"Metabotropic glutamate receptor 7","protein":"Metabotropic glutamate receptor 7"}],"modality":"Small Molecule","drugClass":"dexfosfoserine","explanation":"Imagine your brain cells talking to each other through chemical messengers called neurotransmitters. Seriphos helps control how these messengers are released by binding to a specific receptor on the brain cells. This can affect how the brain cells communicate with each other.","oneSentence":"Seriphos works by binding to the metabotropic glutamate receptor 8, a protein involved in regulating neurotransmitter release.","technicalDetail":"Seriphos, a selective antagonist of the metabotropic glutamate receptor 8 (mGluR8), modulates glutamatergic neurotransmission by reducing the release of glutamate, a key excitatory neurotransmitter."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4120","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXFOSFOSERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:36:53.810423","biosimilars":[],"competitors":[{"drugName":"glutamic acid","drugSlug":"glutamic-acid","fdaApproval":"","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dexfosfoserine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glutamic-acid","brandName":"glutamic acid","genericName":"glutamic acid","approvalYear":"","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"006741","UNII":"VI4F0K069V","CHEBI":"CHEBI:15811","INN_ID":"6888","UMLSCUI":"C5418344","ChEMBL_ID":"CHEMBL284377","DRUGBANK_ID":"DB04522","PDB_CHEM_ID":" SEP","PUBCHEM_CID":"68841","SNOMEDCT_US":"102750006","IUPHAR_LIGAND_ID":"1411","MESH_DESCRIPTOR_UI":"D010768"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Seriphos, also known as dexfosfoserine, is a small molecule modality targeting the metabotropic glutamate receptor 8. Its exact commercial status is unknown, and it has not received FDA approval for any indications. As a drug class, dexfosfoserine is still in the development phase, and its pharmacokinetic properties, such as half-life and bioavailability, are not publicly disclosed. Further research is needed to determine its efficacy and safety profile. The current owner of Seriphos is not specified.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}